Diagnosis and management of Parkinson's disease dementia

International Journal of Clinical Practice

Volumn 62, Issue 10, 2008, Pages 1581-1587

  Poewe, W ^a   Gauthier, S ^b   Aarsland, D ^c,d   Leverenz, J B ^e   Barone, P ^f   Weintraub, D ^g   Tolosa, E ^h   Dubois, B ⁱ  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MCGILL UNIVERSITY   (Canada)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO; RIVASTIGMINE;

CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC TEST; DIARRHEA; DISEASE COURSE; HUMAN; NAUSEA; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREMOR; VOMITING;

CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; PARKINSON DISEASE; PRACTICE GUIDELINES AS TOPIC; PSYCHOLOGICAL TESTS;

EID: 51349133574     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01869.x     Document Type: Review

References (47)

1. de Rijk MC, Launer LJ, Berger K et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000 11 (Suppl. 5 S21 3.
2. Pillon B, Boller F, Levy R, Dubois B. Cognitive deficits and dementia in Parkinson's disease. In : Boller F, Cappa SF, eds. Handbook of Neuropsychology, 2nd edn. Amsterdam : Elsevier Health Sciences, 2001 : 311 71
3. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003 2 : 229 37.
4. Levy G, Schupf N, Tang MX et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002 51 : 722 9.
5. Aarsland D, Andersen K, Larsen JP et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001 56 : 730 6.
6. Buter TC, van den Hout A, Matthews FE et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008 70 : 1017 22.
7. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 2003 18 (Suppl. 6 S72 9.
8. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004 110 : 118 23.
9. Dubois B, Burn D, Goetz C et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord 2007 15 : 22.
10. Emre M, Aarsland D, Brown R et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007 22 : 1689 707.
11. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004 351 : 2509 18.
12. Backman L, Jones S, Berger AK et al. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 2005 19 : 520 31.
13. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006 21 : 1343 9.
14. Caviness JN, Driver-Dunckley E, Connor DJ et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007 22 : 1272 7.
15. Brønnick K, Emre M, Lane R et al. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007 78 : 1064 8.
16. Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001 16 : 184 91.
17. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis 2007 11 : 509 19.
18. Hornykiewicz O. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener Dis 2008 4 : 114 7.
19. Farlow M, Cummings J. A modern hypothesis: the distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dement Geriatr Cogn Disord 2008 25 : 301 8.
20. Kraybill ML, Larson EB, Tsuang DW et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005 64 : 2069 73.
21. Mikolaenko I, Pletnikova O, Kawas CH et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 2005 64 : 156 62.
22. Aarsland D, Perry R, Brown A et al. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005 58 : 773 6.
23. Bohnen NI, Kaufer DI, Ivanco LS et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003 60 : 1745 8.
24. Tiraboschi P, Hansen LA, Alford M et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000 54 : 407 11.
25. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996 61 : 324 5.
26. Fabbrini G, Barbanti P, Aurilia C et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002 23 : 41 3.
27. Kurita A, Ochiai Y, Kono Y et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003 16 : 184 8.
28. Aarsland D, Brønnick K, Karlsen K. Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999 14 : 69 72.
29. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001 16 : 1171 4.
30. Fogelson N, Kogan E, Korczyn AD et al. Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurol Scand 2003 107 : 252 5.
31. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002 18 : 258 64.
32. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003 18 : 937 41.
33. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002 72 : 708 12.
34. Leroi I, Brandt J, Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004 19 : 1 8.
35. Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006 21 : 1899 907.
36. Barone P, Burn DJ, Van T et al. Rivastigmine vs placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 2008 [Epub ahead of print].
37. Dorsey ER, Constantinescu R, Thompson JP et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007 68 : 384 6.
38. Miyasaki JM, Shannon K, Voon V et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 66 : 996 1002.
39. Horstink M, Tolosa E, Bonuccelli U et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006 13 : 1186 202.
40. Waldemar G, Dubois B, Emre M et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007 14 : e1 26.
41. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006, CD004747.
42. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), Arlington, VA : American Psychiatric Association, 4th edn, 1994.
43. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992 55 : 181 4.
44. McKeith IG. Dementia with Lewy bodies. Br J Psychiatry 2002 180 : 144 7.
45. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992 149 : 443 54.
46. Clarke M, Oxman AD. Cochrane Reviewers Handbook 4.1.2. Cochrane Libr, 2001.
47. Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005 76 : 934 9.